Current and Emerging Pharmacotherapy for Fibromyalgia
Introduction. Fibromyalgia syndrome (FMS) is a pain disorder with an estimated prevalence of 1–5%. It is associated with a variety of somatic and psychological disorders. Its exact pathogenesis is still unclear but is involved with neural oversensitization and decreased conditioned pain modulation (...
Gespeichert in:
| Veröffentlicht in: | Pain research & management 2020-02, Vol.2020 (2020), p.1-9, Article 6541798 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9 |
|---|---|
| container_issue | 2020 |
| container_start_page | 1 |
| container_title | Pain research & management |
| container_volume | 2020 |
| creator | Tzadok, Roie Ablin, Jacob N. |
| description | Introduction. Fibromyalgia syndrome (FMS) is a pain disorder with an estimated prevalence of 1–5%. It is associated with a variety of somatic and psychological disorders. Its exact pathogenesis is still unclear but is involved with neural oversensitization and decreased conditioned pain modulation (CPM), combined with cognitive dysfunction, memory impairment, and altered information processing. Connectivity between brain areas involved in pain processing, alertness, and cognition is increased in the syndrome, making its pharmacologic therapy complex. Only three drugs, pregabalin, duloxetine, and milnacipran are currently FDA-approved for FM treatment, but many other agents have been tested over the years, with varying efficacy. Areas Covered. The purpose of this review is to summarize current clinical experience with different pharmacologic treatments used for fibromyalgia and introduce future perspectives in developing therapies. Expert Opinion. Future insights into the fields of cannabinoid and opioid research, as well as an integrative approach towards the incorporation of genetics and functional imaging combined with additional fields of research relevant towards the study of complex CNS disorders, are likely to lead to new developments of novel tailor-made treatments for FMS patients. |
| doi_str_mv | 10.1155/2020/6541798 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_webof</sourceid><recordid>TN_cdi_webofscience_primary_000615585200001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A814686395</galeid><doaj_id>oai_doaj_org_article_0c5dbd36b16144dbabdec86d13947c6a</doaj_id><sourcerecordid>A814686395</sourcerecordid><originalsourceid>FETCH-LOGICAL-c733t-9b1ea63e7a5e5803153c240cc585165977cd628423b2ebbfe6006e4d9d3101e93</originalsourceid><addsrcrecordid>eNqNks-L1DAUx4so7jp68ywDghftbl7SpOlFWIZdXVjQg55Dmry2GdpmTFuX-e_NOOP8AFmGHhrSTz7vpe-bJG-BXAFwfk0JJdeCZ5AX8llyCQXIFDhlz-OaEpaKXPCL5NUwLAnJQBL2MrlgFEjGKVwmfDGFgP04172d33YYatfX8--NDp02fmww6NV6Xvkwv3Nl8N1at7XTr5MXlW4HfLN7z5Kfd7c_Fl_Th29f7hc3D6nJGRvTogTUgmGuOfJYGTgzNCPGcMlB8CLPjRVUZpSVFMuyQkGIwMwWlgEBLNgsud96rddLtQqu02GtvHbq74YPtdJhdKZFRQy3pWWiBAFZZktdWjRSWGBFlhuho-vz1rWayg6tiZcOuj2Rnn7pXaNq_1vlhAkAGQXvd4Lgf004jGrpp9DH-ysaCUloIdiBqnXsyvWVjzLTucGoGwmZkIIV_ElKxOEQkHGEs-TqP1R8LHbO-B4rF_dPtGcdOK7w4ehAg7odm8G30-h8P5yanwSPjZ-2oAl-GAJW-z8MRG0CqzaBVbvARvzd8VT28L-ERuDjFnjE0leDcdgb3GMkBiY6Y-G4Ihtank8v3Kg3_S_81I-HQo3rrX50Z_aNkcFKH2hKREEl-wMm4xcY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2361802963</pqid></control><display><type>article</type><title>Current and Emerging Pharmacotherapy for Fibromyalgia</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley-Blackwell Open Access Titles</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Tzadok, Roie ; Ablin, Jacob N.</creator><contributor>Harth, Manfred ; Manfred Harth</contributor><creatorcontrib>Tzadok, Roie ; Ablin, Jacob N. ; Harth, Manfred ; Manfred Harth</creatorcontrib><description>Introduction. Fibromyalgia syndrome (FMS) is a pain disorder with an estimated prevalence of 1–5%. It is associated with a variety of somatic and psychological disorders. Its exact pathogenesis is still unclear but is involved with neural oversensitization and decreased conditioned pain modulation (CPM), combined with cognitive dysfunction, memory impairment, and altered information processing. Connectivity between brain areas involved in pain processing, alertness, and cognition is increased in the syndrome, making its pharmacologic therapy complex. Only three drugs, pregabalin, duloxetine, and milnacipran are currently FDA-approved for FM treatment, but many other agents have been tested over the years, with varying efficacy. Areas Covered. The purpose of this review is to summarize current clinical experience with different pharmacologic treatments used for fibromyalgia and introduce future perspectives in developing therapies. Expert Opinion. Future insights into the fields of cannabinoid and opioid research, as well as an integrative approach towards the incorporation of genetics and functional imaging combined with additional fields of research relevant towards the study of complex CNS disorders, are likely to lead to new developments of novel tailor-made treatments for FMS patients.</description><identifier>ISSN: 1203-6765</identifier><identifier>EISSN: 1918-1523</identifier><identifier>DOI: 10.1155/2020/6541798</identifier><identifier>PMID: 32104521</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Antidepressants ; Anxiety ; Chronic fatigue syndrome ; Clinical Neurology ; Clinical trials ; Cognition disorders ; Drug therapy ; FDA approval ; Fibromyalgia ; Lacosamide ; Life Sciences & Biomedicine ; Medical research ; Medicine, Experimental ; Mental depression ; Meta-analysis ; Nabilone ; Narcotics ; Neurophysiology ; Neurosciences & Neurology ; Pain ; Quality of life ; Review ; Science & Technology ; Serotonin ; Sleep disorders ; Tetrahydrocannabinol ; THC</subject><ispartof>Pain research & management, 2020-02, Vol.2020 (2020), p.1-9, Article 6541798</ispartof><rights>Copyright © 2020 Roie Tzadok and Jacob N. Ablin.</rights><rights>COPYRIGHT 2020 John Wiley & Sons, Inc.</rights><rights>Copyright © 2020 Roie Tzadok and Jacob N. Ablin. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2020 Roie Tzadok and Jacob N. Ablin. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>59</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000615585200001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c733t-9b1ea63e7a5e5803153c240cc585165977cd628423b2ebbfe6006e4d9d3101e93</citedby><cites>FETCH-LOGICAL-c733t-9b1ea63e7a5e5803153c240cc585165977cd628423b2ebbfe6006e4d9d3101e93</cites><orcidid>0000-0003-2523-4850 ; 0000-0001-9926-891X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036118/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036118/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,879,887,2104,2116,27931,27932,28255,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32104521$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Harth, Manfred</contributor><contributor>Manfred Harth</contributor><creatorcontrib>Tzadok, Roie</creatorcontrib><creatorcontrib>Ablin, Jacob N.</creatorcontrib><title>Current and Emerging Pharmacotherapy for Fibromyalgia</title><title>Pain research & management</title><addtitle>PAIN RES MANAG</addtitle><addtitle>Pain Res Manag</addtitle><description>Introduction. Fibromyalgia syndrome (FMS) is a pain disorder with an estimated prevalence of 1–5%. It is associated with a variety of somatic and psychological disorders. Its exact pathogenesis is still unclear but is involved with neural oversensitization and decreased conditioned pain modulation (CPM), combined with cognitive dysfunction, memory impairment, and altered information processing. Connectivity between brain areas involved in pain processing, alertness, and cognition is increased in the syndrome, making its pharmacologic therapy complex. Only three drugs, pregabalin, duloxetine, and milnacipran are currently FDA-approved for FM treatment, but many other agents have been tested over the years, with varying efficacy. Areas Covered. The purpose of this review is to summarize current clinical experience with different pharmacologic treatments used for fibromyalgia and introduce future perspectives in developing therapies. Expert Opinion. Future insights into the fields of cannabinoid and opioid research, as well as an integrative approach towards the incorporation of genetics and functional imaging combined with additional fields of research relevant towards the study of complex CNS disorders, are likely to lead to new developments of novel tailor-made treatments for FMS patients.</description><subject>Antidepressants</subject><subject>Anxiety</subject><subject>Chronic fatigue syndrome</subject><subject>Clinical Neurology</subject><subject>Clinical trials</subject><subject>Cognition disorders</subject><subject>Drug therapy</subject><subject>FDA approval</subject><subject>Fibromyalgia</subject><subject>Lacosamide</subject><subject>Life Sciences & Biomedicine</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mental depression</subject><subject>Meta-analysis</subject><subject>Nabilone</subject><subject>Narcotics</subject><subject>Neurophysiology</subject><subject>Neurosciences & Neurology</subject><subject>Pain</subject><subject>Quality of life</subject><subject>Review</subject><subject>Science & Technology</subject><subject>Serotonin</subject><subject>Sleep disorders</subject><subject>Tetrahydrocannabinol</subject><subject>THC</subject><issn>1203-6765</issn><issn>1918-1523</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>AOWDO</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNks-L1DAUx4so7jp68ywDghftbl7SpOlFWIZdXVjQg55Dmry2GdpmTFuX-e_NOOP8AFmGHhrSTz7vpe-bJG-BXAFwfk0JJdeCZ5AX8llyCQXIFDhlz-OaEpaKXPCL5NUwLAnJQBL2MrlgFEjGKVwmfDGFgP04172d33YYatfX8--NDp02fmww6NV6Xvkwv3Nl8N1at7XTr5MXlW4HfLN7z5Kfd7c_Fl_Th29f7hc3D6nJGRvTogTUgmGuOfJYGTgzNCPGcMlB8CLPjRVUZpSVFMuyQkGIwMwWlgEBLNgsud96rddLtQqu02GtvHbq74YPtdJhdKZFRQy3pWWiBAFZZktdWjRSWGBFlhuho-vz1rWayg6tiZcOuj2Rnn7pXaNq_1vlhAkAGQXvd4Lgf004jGrpp9DH-ysaCUloIdiBqnXsyvWVjzLTucGoGwmZkIIV_ElKxOEQkHGEs-TqP1R8LHbO-B4rF_dPtGcdOK7w4ehAg7odm8G30-h8P5yanwSPjZ-2oAl-GAJW-z8MRG0CqzaBVbvARvzd8VT28L-ERuDjFnjE0leDcdgb3GMkBiY6Y-G4Ihtank8v3Kg3_S_81I-HQo3rrX50Z_aNkcFKH2hKREEl-wMm4xcY</recordid><startdate>20200211</startdate><enddate>20200211</enddate><creator>Tzadok, Roie</creator><creator>Ablin, Jacob N.</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>Hindawi Publishing Group</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M3G</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2523-4850</orcidid><orcidid>https://orcid.org/0000-0001-9926-891X</orcidid></search><sort><creationdate>20200211</creationdate><title>Current and Emerging Pharmacotherapy for Fibromyalgia</title><author>Tzadok, Roie ; Ablin, Jacob N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c733t-9b1ea63e7a5e5803153c240cc585165977cd628423b2ebbfe6006e4d9d3101e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antidepressants</topic><topic>Anxiety</topic><topic>Chronic fatigue syndrome</topic><topic>Clinical Neurology</topic><topic>Clinical trials</topic><topic>Cognition disorders</topic><topic>Drug therapy</topic><topic>FDA approval</topic><topic>Fibromyalgia</topic><topic>Lacosamide</topic><topic>Life Sciences & Biomedicine</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mental depression</topic><topic>Meta-analysis</topic><topic>Nabilone</topic><topic>Narcotics</topic><topic>Neurophysiology</topic><topic>Neurosciences & Neurology</topic><topic>Pain</topic><topic>Quality of life</topic><topic>Review</topic><topic>Science & Technology</topic><topic>Serotonin</topic><topic>Sleep disorders</topic><topic>Tetrahydrocannabinol</topic><topic>THC</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tzadok, Roie</creatorcontrib><creatorcontrib>Ablin, Jacob N.</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>CBCA Reference & Current Events</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pain research & management</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tzadok, Roie</au><au>Ablin, Jacob N.</au><au>Harth, Manfred</au><au>Manfred Harth</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current and Emerging Pharmacotherapy for Fibromyalgia</atitle><jtitle>Pain research & management</jtitle><stitle>PAIN RES MANAG</stitle><addtitle>Pain Res Manag</addtitle><date>2020-02-11</date><risdate>2020</risdate><volume>2020</volume><issue>2020</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><artnum>6541798</artnum><issn>1203-6765</issn><eissn>1918-1523</eissn><abstract>Introduction. Fibromyalgia syndrome (FMS) is a pain disorder with an estimated prevalence of 1–5%. It is associated with a variety of somatic and psychological disorders. Its exact pathogenesis is still unclear but is involved with neural oversensitization and decreased conditioned pain modulation (CPM), combined with cognitive dysfunction, memory impairment, and altered information processing. Connectivity between brain areas involved in pain processing, alertness, and cognition is increased in the syndrome, making its pharmacologic therapy complex. Only three drugs, pregabalin, duloxetine, and milnacipran are currently FDA-approved for FM treatment, but many other agents have been tested over the years, with varying efficacy. Areas Covered. The purpose of this review is to summarize current clinical experience with different pharmacologic treatments used for fibromyalgia and introduce future perspectives in developing therapies. Expert Opinion. Future insights into the fields of cannabinoid and opioid research, as well as an integrative approach towards the incorporation of genetics and functional imaging combined with additional fields of research relevant towards the study of complex CNS disorders, are likely to lead to new developments of novel tailor-made treatments for FMS patients.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>32104521</pmid><doi>10.1155/2020/6541798</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2523-4850</orcidid><orcidid>https://orcid.org/0000-0001-9926-891X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1203-6765 |
| ispartof | Pain research & management, 2020-02, Vol.2020 (2020), p.1-9, Article 6541798 |
| issn | 1203-6765 1918-1523 |
| language | eng |
| recordid | cdi_webofscience_primary_000615585200001 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley-Blackwell Open Access Titles; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central; Alma/SFX Local Collection |
| subjects | Antidepressants Anxiety Chronic fatigue syndrome Clinical Neurology Clinical trials Cognition disorders Drug therapy FDA approval Fibromyalgia Lacosamide Life Sciences & Biomedicine Medical research Medicine, Experimental Mental depression Meta-analysis Nabilone Narcotics Neurophysiology Neurosciences & Neurology Pain Quality of life Review Science & Technology Serotonin Sleep disorders Tetrahydrocannabinol THC |
| title | Current and Emerging Pharmacotherapy for Fibromyalgia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T04%3A39%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20and%20Emerging%20Pharmacotherapy%20for%20Fibromyalgia&rft.jtitle=Pain%20research%20&%20management&rft.au=Tzadok,%20Roie&rft.date=2020-02-11&rft.volume=2020&rft.issue=2020&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.artnum=6541798&rft.issn=1203-6765&rft.eissn=1918-1523&rft_id=info:doi/10.1155/2020/6541798&rft_dat=%3Cgale_webof%3EA814686395%3C/gale_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2361802963&rft_id=info:pmid/32104521&rft_galeid=A814686395&rft_doaj_id=oai_doaj_org_article_0c5dbd36b16144dbabdec86d13947c6a&rfr_iscdi=true |